Description of the host plant |
Please refer Agriculture and Agri-Food Canada’s Regulatory Directive Dir. BIO1996-10; The Biology of Glycine max (L..) Merr. (Soybean)
http://www.inspection.gc.ca/english/plaveg/bio/dir/t11096e.shtml |
Description of the Modification |
The PNT was developed through recombinant DNA technology. In order to assess the modification process, the following has been submitted:
- Description of the transformation system/modification process
- Description of the transformation method
- Nature and source of the carrier DNA
- Description of the genetic material delivered to the plant
- Components of the vector
- Summary of all genetic components
- Description of the herbicide tolerance gene – cp4 epsps
- Description of the promoter and terminator
- Portion and size of the inserted sequence
- Location, order and orientation in the vector
- Function of the cp4 epsps gene in the plant
- Source of the cp4 epsps gene (donor organism – bacteria)
- Level of expression of CP4 EPSPS protein in forage and grain
- Review of the toxicity and pathogenic ability of the genetic components to plants and other organisms
- Review of the toxicity and pathogenic ability of the donor organisms to plants and other organisms
- History of use of the cp4 epsps gene
- Detailed map of the vector
|
Inheritance and Stability of the Introduced Trait |
In order to assess the inheritance and stability of the genetic modification, the following has been submitted:
- Analysis of stability over multiple generations
|
Description of the Novel Trait |
In order to characterize the DNA inserted in the plant, the following has been submitted:
- Information for all coding areas
- Information on plant promoters: Southern analysis of the cp4 epsps coding region and its promoter Southern analyses of other genetic elements that are incorporated into the soybean genome but are not expressed
- Characterization of expressed CP4 EPSPS protein in soybean
|
Toxicity of the Novel Gene Products |
The toxicity of the CP4 protein on pest and non-pest species, humans and animals. The following have been previously submitted, reviewed, and published:
- Decision Document DD95-02: Determination of Environmental Safety of Monsanto Canada Inc.’s Roundup Ready® Herbicide-Tolerant Brassica napus Canola Line GT73
- Decision Document DD95-05: Determination of Environmental Safety of Monsanto Canada Inc.’s Glyphosate Tolerant Soybean (Glycine max
L.) Line GTS 40-3-2
- Decision Document 2002-35: Determination of Safety of Monsanto Canada Inc.’s Roundup Ready® Corn (Zea mays L) Line 603
- Decision Document 2005-53: Determination of Safety of Monsanto Canada Inc.’s Roundup Ready® Alfalfa (Medicago sativa
L) Events J101 and J163
- Decision Document 2005-54: Determination of Safety of Monsanto Canada Inc.’s and KWS SAAT AG’s Roundup Ready® Sugar Beet (Beta vulgaris spp vulgaris
L.) Event H7-1
- Decision Document 2005-56: Determination of Safety of Monsanto Canada Inc.’s Roundup Ready® Flex Cotton (Gossypium hirsutum
L) Line MON 88913
- Decision Document 2006-57: Determination of Safety of Monsanto Canada Inc.’s Glyphosate-Tolerant, Corn-Rootworm-Protected Corn (Zea mays L.) Event MON 88017
- Hammond, B. R.L. Fuchs et al. 1996. The feeding value of soybeans fed to rats, chickens, catfish, and dairy cattle is not altered by genetic incorporation of glyphosate
tolerance. J. Nutr. 126: 717-727.
- Harrison, L., M. et al. 1996. The expressed protein in glyphosate-tolerant soybean, 5-enolpyruvylshikimate-3-phosphate synthase from Agrobacterium sp. strain CP4, is rapidly digested in vitro and is not toxic to acutely gavaged
mice. J. Nutr. 126:728-740.
- McCann, M. et al. 2005. Glyphosate-tolerant soybeans remain compositionally equivalent to conventional soybeans (Glycine max L) during three years of field testing. J. Ag. & Food Chem. 53(13): 5331-5335
- Park, J. et al. 2001. Comparison of allergens in genetically modified soybean with conventional soybean. Yahak Hoeji. 45(3): 293-301
|
Nutritional Evaluation of the Novel Plant |
In order to assess nutritional aspects of the novel plant, the following has been submitted:
- The nutritional composition of the novel plant has been compared to unmodified soybean. The following have been considered:
- Proximate composition (protein, fat, ash, carbohydrates)
- Composition of amino acids, fatty acids, and minerals
- Acid detergent fiber and neutral detergent fiber
- Micro-nutritional elements (vitamins, etc) and anti-nutrients for soybean
|
Allergenicity/ Toxicity Considerations |
In order to assess allergenicity and toxicity of the novel proteins, the following has been submitted:
- Comparison of the amino acid sequence similarity of cp4 epsps protein expressed in MON 89788 to known protein allergens or toxins through bioinformatics analysis
The following has been previously submitted:
- Analysis the amino acid sequence similarity of cp4 epsps or protein expressed in other crops or products to known protein allergens or toxins through bioinformatics analysis
|
Evaluation of the Environmental Impact of the Novel Plant |
In order to assess the environmental impact of the novel plant, the following has been submitted:
- Examination for potential weediness of the PNT
- Examination of seed yield of the PNT
- Examination of reproductive features of the PNT
- Examination of phenotypic characteristics of the PNT
- Examination of seed dormancy and germination of the PNT
- Examination of the response to biotic and abiotic stressors on the PNT
- Examination of the PNT’s potential to become a plant pest
- Examination of gene flow from the PNT to wild relatives based on literature
- Examination of plant pest and non-pest impacts of the PNT
- Stewardship and mitigation plans
|
Comments will be received only via the Internet or postal mail to CFIA or Health Canada. (See addresses below.)
For more information on this product, please contact:
Monsanto Canada Inc.
350 Albert Street, Suite 315
Ottawa ON K1R 1A4
(613) 234-5121
For more information on the regulatory system, please contact:
Feed Section
Animal Products Directorate
Canadian Food Inspection Agency
59 Camelot Drive
Nepean, Ontario
K1A 0Y9
(613) 225-2342 |
Novel Foods Section
Food Directorate
Health Products and Food Branch
Health Canada
Tunneys Pasture
Ottawa, Ontario
K1A 0L2
(613) 954-8921 |
Plant Biosafety
Office
Plant Products Directorate
Canadian Food Inspection Agency
59 Camelot Drive
Nepean, Ontario
K1A 0Y9
(613) 225-2342 |
The CFIA and Health Canada, including
their employees, are not responsible for the content of this Notice of
Submission as submitted by the Applicant. All Notices of Submission are the
responsibility of the Applicant submitting them and the Applicant does so at
its own risk. Submission of this Notice of Submission and its subsequent
posting by the CFIA
on its Web site does not in any way whatsoever constitute acceptance, approval
or certification by the CFIA or Health Canada of the Plant
with Novel Trait(s) subject of the Notice of Submission and the CFIA and Health Canada reserve all
their rights under all the pertinent legislation that may be applicable. The
CFIA and Health
Canada in no way whatsoever waives any of their rights under any of the
legislation they enforce or administer by way of the CFIA posting this Notice of
Submission.
The Applicant is not obliged to provide any information.
The Applicant submits information that it chooses to submit. The information
that the Applicant voluntarily provides on this Notice of Submission is
collected by the CFIA and Health Canada for the
purpose of sharing information with the public. Personal Information will be
protected under the provisions of the Privacy Act, and will
be stored in Personal Information Bank CFIA PPU 125. Information, including
personal information, may be accessible or protected as required under the
provisions of the Access to Information Act.
The CFIA and Health Canada reserve the
right at any time to edit or remove, from any submitted comments prior to
posting them, any content which is or may be in our opinion harmful or offensive
in any way to any person or where complaints are received in respect of such
content. We will not be liable to any person who has submitted such content,
irrespective of any such editing or removal.
The CFIA and Health Canada do not
endorse or oppose any opinions expressed in the public's comments as posted on
this website. |